Soluble truncated forms of ICAM-1
AssigneeBayer Aktiengesellschaft
InventorsJeffrey M. Greve, Alan McClelland, Gary Davis
Life of this patent
Estimating the term…
Abstract
Novel analogs of ICAM-1 and methods of using same for reducing human rhinovirus infection.
Claims12
An antiviral analog of ICAM-1 comprising domain I wherein amino acid residues Thr-2/Ser-3Val-4/Ser-5 (SEQ ID NO:
- 16) have been changed to Val- 2/Ser-3/Ile-4/His-5 (SEQ ID NO:
- 7).
An antiviral analog of ICAM-1 comprising domain I wherein amino acid residue Leu-30 has been changed to Ser-30.
An antiviral analog of ICAM-1 comprising domain I in which amino acid residues Pro-36/Leu-37/Pro-38 have been changed to Gln-36/Trp-37/Leu-38.
(amended) An antiviral analog of ICAM-1 comprising domain I in which amino acid residues Leu44/Pro45/Gly46/Asn-47 (SEQ ID NO:
- 16 have been changed to Glu 44/Ser45/Gly46/Pro-47 (SEQ ID NO:
- 17).
An antiviral analog of ICAM-1 comprising domain I in which amino acid residue Gln-58 has been changed to His-58.
An antiviral analog of ICAM-1 comprising domain I in which amino acid residues Thr-78/Phe-79/Leu-80 have been changed to Ala-78/Thr-79/Ile-80.
Dependencies are inferred from the claim text.